PMC5387803_01
Development of aPTT, factor VIII, and inhibitor titer. Biological development before and after initial presentation in the emergency room. Dotted lines represent the limit of reference values. Corticosteroids (CS) were administered daily after presentation; rituximab (R) was administered once a week for 4 consecutive weeks (from Day 14).
CRIHEM2017-2057019.001.jpg
PMC5387803_01_CRIHEM2017-2057019.001.jpg
fig1
We therefore assume that the patient developed FVIII inhibitors at least 6 months before bleeding manifestations occurred (Figure 1). In less than 12 weeks, we completely eradicated the FVIII inhibitor and restored normal FVIII levels (>100%) and normal aPTT (Figure 1).
Development of anti-BP180 and BP230 titers. Follow-up of BP activity before and after AHA. Dotted lines represent the limit of normal values.
CRIHEM2017-2057019.002.jpg
PMC5387803_01_CRIHEM2017-2057019.002.jpg
fig2
In the meantime, anti-BP180 and BP230 titers developed favorably as well (Figure 2).